CY1113457T1 - 2-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-3-φαινυλο πυραζινες και πυριδινες και 3-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-2-φαινυλο πυριδινες ως ανταγωνιστες του υποδοχεα 5-ητ7 - Google Patents
2-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-3-φαινυλο πυραζινες και πυριδινες και 3-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-2-φαινυλο πυριδινες ως ανταγωνιστες του υποδοχεα 5-ητ7Info
- Publication number
- CY1113457T1 CY1113457T1 CY20121101219T CY121101219T CY1113457T1 CY 1113457 T1 CY1113457 T1 CY 1113457T1 CY 20121101219 T CY20121101219 T CY 20121101219T CY 121101219 T CY121101219 T CY 121101219T CY 1113457 T1 CY1113457 T1 CY 1113457T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ylalkyl
- pyrazol
- pyridines
- piperazin
- piperazine
- Prior art date
Links
- 108091005436 5-HT7 receptors Proteins 0.000 title abstract 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91743107P | 2007-05-11 | 2007-05-11 | |
| US97420907P | 2007-09-21 | 2007-09-21 | |
| EP08747748A EP2155717B1 (en) | 2007-05-11 | 2008-05-07 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113457T1 true CY1113457T1 (el) | 2016-06-22 |
Family
ID=39629131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121101219T CY1113457T1 (el) | 2007-05-11 | 2012-12-13 | 2-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-3-φαινυλο πυραζινες και πυριδινες και 3-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-2-φαινυλο πυριδινες ως ανταγωνιστες του υποδοχεα 5-ητ7 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8202873B2 (enExample) |
| EP (1) | EP2155717B1 (enExample) |
| JP (1) | JP5210375B2 (enExample) |
| KR (1) | KR101119294B1 (enExample) |
| CN (1) | CN101861312B (enExample) |
| AU (1) | AU2008251584B2 (enExample) |
| BR (1) | BRPI0811446A2 (enExample) |
| CA (1) | CA2684563C (enExample) |
| CY (1) | CY1113457T1 (enExample) |
| DK (1) | DK2155717T3 (enExample) |
| EA (1) | EA016529B1 (enExample) |
| ES (1) | ES2395872T3 (enExample) |
| HR (1) | HRP20120919T1 (enExample) |
| MX (1) | MX2009012126A (enExample) |
| PL (1) | PL2155717T3 (enExample) |
| PT (1) | PT2155717E (enExample) |
| WO (1) | WO2008141020A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101910159B (zh) * | 2007-12-26 | 2013-06-19 | 卫材R&D管理有限公司 | 杂环取代吡啶衍生物的制备方法 |
| US8563747B2 (en) | 2009-07-31 | 2013-10-22 | Syngenta Crop Protection, Llc | Processes for the alkylation of pyrazoles |
| JPWO2011062194A1 (ja) | 2009-11-18 | 2013-04-04 | 武田薬品工業株式会社 | アミノピリジン誘導体 |
| EP2566333A4 (en) * | 2010-05-07 | 2014-04-02 | Univ Leland Stanford Junior | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS |
| PT2603494T (pt) * | 2010-08-10 | 2017-02-03 | Syngenta Participations Ag | Processo para a preparação de 3-haloalquilopirazóis |
| MX2016008130A (es) | 2013-12-20 | 2016-10-13 | Esteve Labor Dr | Derivados de piperidina con actividad multimodal contra el dolor. |
| WO2016025129A1 (en) | 2014-08-14 | 2016-02-18 | Alhamadsheh Mamoun M | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| CN104592199A (zh) * | 2015-01-22 | 2015-05-06 | 杭州利巴医药科技有限公司 | 一种取代的1-(2-吡啶基)-吡唑-4-基乙酸及其衍生物和制备方法 |
| CN104945325B (zh) * | 2015-06-19 | 2017-04-05 | 浙江永太科技股份有限公司 | 一种吡唑甲酸衍生物的制备方法 |
| CN116730920A (zh) | 2017-02-17 | 2023-09-12 | 文涵治疗有限公司 | Ag-10的制备方法、其中间体及其盐 |
| TWI817999B (zh) | 2018-03-23 | 2023-10-11 | 美商文涵治療有限公司 | 使用ag10治療ttr澱粉樣沉積症之方法 |
| SI3836920T1 (sl) | 2018-08-17 | 2026-02-27 | Eidos Therapeutics, Inc. | Formulacije AG10 |
| KR102514860B1 (ko) * | 2020-12-01 | 2023-03-29 | 한국과학기술연구원 | 5-ht7 세로토닌 수용체 활성 저해용 바이페닐 피롤리딘 및 바이페닐 다이하이드로이미다졸 유도체 및 이를 유효성분으로 포함하는 약학 조성물 |
| WO2022221451A2 (en) * | 2021-04-13 | 2022-10-20 | University Of Virginia Patent Foundation | Sulfonyl-triazole compounds useful as ligands and inhibitors of prostaglandin reductase 2 |
| CN115974785A (zh) * | 2022-12-09 | 2023-04-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种3,5-二取代吡唑类化合物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2079323B1 (es) * | 1994-06-21 | 1996-10-16 | Vita Invest Sa | Derivados de indol utiles para el tratamiento de la migraña, composicion y uso correspondientes. |
| EP1676844A1 (en) * | 2004-12-28 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
| CA2514656A1 (en) * | 2003-01-31 | 2004-08-12 | Pfizer Products Inc. | 5ht7 antagonists and inverse agonists |
| US20050080076A1 (en) * | 2003-10-08 | 2005-04-14 | Xanodyne Pharmacal, Inc. | N-desmethyl levomepromazine |
-
2008
- 2008-05-07 ES ES08747748T patent/ES2395872T3/es active Active
- 2008-05-07 AU AU2008251584A patent/AU2008251584B2/en not_active Ceased
- 2008-05-07 HR HRP20120919AT patent/HRP20120919T1/hr unknown
- 2008-05-07 CN CN200880015741.XA patent/CN101861312B/zh not_active Expired - Fee Related
- 2008-05-07 WO PCT/US2008/062834 patent/WO2008141020A1/en not_active Ceased
- 2008-05-07 DK DK08747748.5T patent/DK2155717T3/da active
- 2008-05-07 JP JP2010507607A patent/JP5210375B2/ja not_active Expired - Fee Related
- 2008-05-07 KR KR1020097022901A patent/KR101119294B1/ko not_active Expired - Fee Related
- 2008-05-07 MX MX2009012126A patent/MX2009012126A/es active IP Right Grant
- 2008-05-07 PT PT87477485T patent/PT2155717E/pt unknown
- 2008-05-07 EA EA200971052A patent/EA016529B1/ru not_active IP Right Cessation
- 2008-05-07 CA CA2684563A patent/CA2684563C/en not_active Expired - Fee Related
- 2008-05-07 PL PL08747748T patent/PL2155717T3/pl unknown
- 2008-05-07 BR BRPI0811446-3A2A patent/BRPI0811446A2/pt not_active Application Discontinuation
- 2008-05-07 US US12/597,255 patent/US8202873B2/en not_active Expired - Fee Related
- 2008-05-07 EP EP08747748A patent/EP2155717B1/en not_active Not-in-force
-
2012
- 2012-12-13 CY CY20121101219T patent/CY1113457T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2155717E (pt) | 2012-12-21 |
| EP2155717A1 (en) | 2010-02-24 |
| EA016529B1 (ru) | 2012-05-30 |
| AU2008251584A1 (en) | 2008-11-20 |
| MX2009012126A (es) | 2009-11-23 |
| JP2010526819A (ja) | 2010-08-05 |
| EA200971052A1 (ru) | 2010-04-30 |
| KR101119294B1 (ko) | 2012-04-12 |
| HRP20120919T1 (hr) | 2012-12-31 |
| BRPI0811446A2 (pt) | 2014-10-29 |
| JP5210375B2 (ja) | 2013-06-12 |
| DK2155717T3 (da) | 2012-11-19 |
| CN101861312A (zh) | 2010-10-13 |
| US8202873B2 (en) | 2012-06-19 |
| KR20090127436A (ko) | 2009-12-11 |
| CN101861312B (zh) | 2014-09-03 |
| PL2155717T3 (pl) | 2013-03-29 |
| ES2395872T3 (es) | 2013-02-15 |
| EP2155717B1 (en) | 2012-10-24 |
| US20100120785A1 (en) | 2010-05-13 |
| WO2008141020A1 (en) | 2008-11-20 |
| CA2684563C (en) | 2013-08-13 |
| AU2008251584B2 (en) | 2013-04-11 |
| CA2684563A1 (en) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113457T1 (el) | 2-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-3-φαινυλο πυραζινες και πυριδινες και 3-[4-(πυραζολ-4-υλαλκυλ)πιπεραζιν-1-υλ]-2-φαινυλο πυριδινες ως ανταγωνιστες του υποδοχεα 5-ητ7 | |
| CY1116333T1 (el) | Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr | |
| CY1109656T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
| CY1115789T1 (el) | 2,3-διυδροβενζο[1,4]διοξιν-2-υλομεθυλο παραγωγα ως αλφα2c ανταγωνιστες για χρηση στη θεραπευτικη αγωγη παθησεων του περιφερικου και του κεντρικου νευρικου συστηματος | |
| CY1122279T1 (el) | Ενωσεις ναφθυριδινης αναστολεις κινασης jak | |
| CY1118772T1 (el) | Νεες συγχωνευμενες πυριδινικες ενωσεις ως αναστολεις κινασης της καζεϊνης | |
| CY1114861T1 (el) | Παραγωγα 3-αρυλαμινοπυριδινης | |
| MX381588B (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
| MX389142B (es) | Compuestos espiro triciclicos. | |
| CY1119252T1 (el) | Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40 | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| CY1105080T1 (el) | Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης | |
| CY1118340T1 (el) | Αναστολεις κινασης | |
| JP2018507877A5 (enExample) | ||
| BR112014010271A2 (pt) | compostos de benzenossulfonamida e seu uso como agentes terapêuticos | |
| DOP2012000153A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes | |
| CY1115836T1 (el) | Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων | |
| UY30500A1 (es) | Compuestos de azabencimidazolilo | |
| CY1117726T1 (el) | Θετικοι αλλοστερικοι ρυθμιστες υποδοχεα μ1 κινολιναμιδιου | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| UY31189A1 (es) | Compuestos heterocíclicos | |
| EA200700099A1 (ru) | Производные пиридина | |
| AR077252A1 (es) | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos | |
| PE20191557A1 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y metodos para tratar enfermedades y trastornos relacionados con ire1 |